--- title: "A&G PHARMACEUTICAL, INC. — Capability Statement" uei: "SN6SWFABJXL1" cage: "1T9L5" canonical: "https://teamingindex.com/contractor/SN6SWFABJXL1/capability.md" html_url: "https://teamingindex.com/contractor/SN6SWFABJXL1" updated: "2026-11-09T17:28:18.052Z" generator: "TeamingIndex capability twin 1.0" legal_name: "A&G PHARMACEUTICAL, INC." dba_name: "PRECISION ANTIBODY" primary_naics: "541714" sam_status: "active" active_exclusion: false claimed: false tier: "unclaimed" --- # A&G PHARMACEUTICAL, INC. > A&G PHARMACEUTICAL, INC. (DBA PRECISION ANTIBODY) is a SAM.gov-registered entity based in COLUMBIA, MD 21045-2006. UEI SN6SWFABJXL1; CAGE 1T9L5; primary NAICS 541714. Compliance posture not provided. Active SAM registration. > **Unclaimed profile:** seeded from SAM.gov and USAspending public records. The entity has not claimed it, so capabilities and compliance posture have not been provided. ## Identifiers - **Legal business name:** A&G PHARMACEUTICAL, INC. - **DBA name:** PRECISION ANTIBODY - **UEI (SAM.gov Unique Entity ID):** SN6SWFABJXL1 - **CAGE code:** 1T9L5 - **Entity structure:** Corporate Entity (Not Tax Exempt) - **State of incorporation:** DE - **Website:** - **TeamingIndex profile:** - **Profile status:** Unclaimed · seeded from SAM.gov and USAspending public records ## Location - **Physical address (city, state, ZIP):** COLUMBIA, MD 21045-2006 - **Country:** United States - **Congressional district:** MD-03 ## NAICS & PSC | NAICS | Title | Primary | Small under SBA size standard (SAM.gov) | | --- | --- | --- | --- | | 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | Yes | Yes | | 325412 | Pharmaceutical Preparation Manufacturing | No | Yes | | 325413 | — | No | Yes | | 541690 | Other Scientific and Technical Consulting Services | No | Yes | | 621511 | Medical Laboratories | No | Yes | | PSC | Name | | --- | --- | | 6505 | DRUGS AND BIOLOGICALS | | 6550 | IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | | AN13 | HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT | | AN22 | HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; APPLIED RESEARCH | | B504 | SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL | - **PSC names:** Acquisition.gov PSC Manual (April 2025 edition) Size status is NAICS-specific and reflects the entity’s SAM.gov representations; check it against the size standard of the solicitation’s NAICS code. ## Socio-economic status - Small Business (SB) Source: SAM.gov entity registration, synced 2026-11-09. Confirm current SBA certification (8(a), HUBZone, WOSB/EDWOSB, VetCert SDVOSB/VOSB) before relying on a status for a set-aside. ## SAM registration & exclusion screening - **Registration:** Active SAM registration - **Registration expires:** 2027-09-21 - **Registration activated:** 2026-09-22 - **Exclusion screening (FAR subpart 9.4):** No active exclusion recorded in SAM.gov - **Teaming eligibility:** Eligible to be proposed as a team member (active registration, no exclusion) - **Source:** SAM.gov Entity Management, synced 2026-11-09 ## Compliance posture Compliance posture not provided by the contractor. - Facility clearance: visible to paid members - Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). ## Contract vehicles No contract vehicle holdings on file. ## Past performance - **Total obligated, trailing 36 months (USAspending.gov):** $0 - **Award history:** 0 awards on record No federal prime awards on record (USAspending.gov). ## Proven teaming graph - No first-tier sub-award reports name this company yet - Source: USAspending.gov sub-award reports (FSRS), sync date not recorded. Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values. ## SBIR/STTR portfolio - SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects - 15 SBIR/STTR awards totaling $10.2M: SBIR Phase I 9, SBIR Phase II 6 - By agency: Department of Health and Human Services 15 - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2020, Sep 1, 2020 to Feb 28, 2023: Pharmacology and human Phase 1 safety and dose escalation studies using anti-GP88 in aggressive breast cancer ($1,889,054) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2018, Sep 1, 2018 to Aug 31, 2021: Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer ($159,365) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2018, Sep 1, 2018 to Aug 31, 2023: A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer ($1,313,828) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2017, Sep 15, 2017 to Aug 31, 2019: Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies ($1,988,100) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2017, Mar 15, 2017 to Mar 14, 2018: A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer ($152,589) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2015: IGF OT IGF SMART FUSION HIGH AFFINITY PEPTIDE CAPTURE REAGENTS ($1,000,000) - SBIR Phase II, Department of Health and Human Services (National Institutes of Health), 2014: Title: Development of Novel Anticancer Agent to potentiate sensitivity to anti-estrogen therapy PoP: 09/19/2014 to 09/18/2016 ($1,478,552) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2013: IGF::OT::IGF Title: SMART Fusion: High Affinity Peptide Capture Reagents PoP: 0 ($199,828) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2012: Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility Studies ($193,879) - SBIR Phase I, Department of Health and Human Services (National Institutes of Health), 2012: NOVEL AGENT TO RESTORE SENSITIVITY TO ANTI-ESTROGEN THERAPY ($199,380) - Phase III: Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual. - Source: SBIR.gov award data file, as of Nov 12, 2026 (file published Nov 1, 2026) ## FedRAMP offerings - No FedRAMP Marketplace listing is linked to this company - Source: FedRAMP Marketplace, sync date not recorded ## Exclusions & screening - Not yet checked against SAM.gov exclusions (search exclusions on SAM.gov: https://sam.gov/search/?index=ex) - Source: SAM.gov Exclusions, sync date not recorded - No confirmed match on the Consolidated Screening List (screened Nov 12, 2026) ## Contract vehicles on federal record - No contract-vehicle seats on federal record are linked to this company ## GSA CALC+ rates - No GSA CALC+ awarded ceiling rates on record for this company - Source: GSA CALC+ awarded ceiling rates, sync date not recorded. Ceiling rates are the most an agency can be charged, not prices paid ## Capabilities & differentiators No capability narrative published. ## Technical tags No technical tags published. ## Teaming preferences - Teaming preferences not published - **Teaming requests and NDAs:** request an introduction on the TeamingIndex profile (sign-in required): ## Business development contact No business-development contact published. ## Corporate hierarchy - No parent entity reported in SAM.gov - Affiliation with a parent or sister concerns can affect small-business size status (13 CFR 121.103). ## Provenance & disclaimer - **SAM.gov entity registration** (identifiers, NAICS/PSC, size and socio-economic status, hierarchy, registration and exclusion status): synced 2026-11-09 - **USAspending.gov** (prime award history and trailing 36-month obligations): nightly sync - **Contractor-provided profile** (capabilities, teaming preferences, self-attested compliance): not provided - **TeamingIndex verification** (credentials marked “Verified by TeamingIndex”): no verified credentials on record; methodology: - **Blind SPRS:** exact NIST SP 800-171 SPRS scores are published only when the contractor opts in; brackets are cumulative thresholds (SPRS ≥ 0, SPRS ≥ 50, SPRS ≥ 70, SPRS ≥ 85, SPRS ≥ 95, SPRS ≥ 105, SPRS = 110 (perfect)). - **Before award:** self-attested facts have not been independently verified. Confirm registration and exclusions in SAM.gov, CMMC status and SPRS assessment currency with the contractor (DFARS 252.204-7019, -7020 and -7021), facility clearances through DCSA’s NISS, AS9100-series certificates in the IAQG OASIS database, and FedRAMP authorizations on the FedRAMP Marketplace. - **Zero CUI:** this document contains no Controlled Unclassified Information. TeamingIndex stores verification metadata only, never SSPs, POA&Ms or DD Form 254s. - **Machine-readable:** schema.org JSON-LD is embedded in ; this twin: ; site index: © 2026 HILARTECH, LLC. All rights reserved. TeamingIndex.com is an independent defense industrial base intelligence platform owned and operated by HILARTECH, LLC and is not affiliated with or endorsed by the U.S. Department of Defense (DoD), the General Services Administration (GSA), or SAM.gov.